by secretary@indianrheumatology.org | Aug 7, 2024 | June 2024
Quarter in review: Clinical Science Siddharth Jain MD, DM (Clinical Immunology and Rheumatology), MRCP (UK),Assistant Professor, Department of Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi Study in focus 1: CD19 CAR T-Cell Therapy in Autoimmune...
by secretary@indianrheumatology.org | Aug 7, 2024 | June 2024
Quarter in Review: Basic Science Upendra Rathore MBBS, MD, DNB, DM (Clinical Immunology and Rheumatology),Assistant Professor, Department of Clinical Immunology and Rheumatology, SGPGI, Lucknow Study in focus 1: Endothelial cells drive organ fibrosis in mice by...
by secretary@indianrheumatology.org | Aug 7, 2024 | June 2024
Tips for Reading Randomized Controlled Trials Mike Putman MD, MSciRheumatologist, Associate Program Director of Internal Medicine, Associate Program Director of Rheumatology, Medical Director Vasculitis ProgramAssistant Professor of Medicine, Division of Rheumatology,...
by secretary@indianrheumatology.org | Aug 7, 2024 | June 2024
Finding your research interest in Rheumatology Amita Aggarwal MD, DM (Clinical Immunology and Rheumatology),Professor & Head, Department of Clinical Immunology & Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 1. What initially...
by secretary@indianrheumatology.org | Aug 7, 2024 | June 2024
JAK inhibitors and Comorbidities Sanat Phatak MD, DM, MRCPAssociate Consultant, Rheumatology & Immunology, KEM Hospital, Pune, Maharashtra JAK inhibitors, chiefly baricitinib and tofacitinib received US-FDA approval for use in multiple rheumatological illnesses...
by secretary@indianrheumatology.org | Aug 7, 2024 | June 2024
Comorbidities in Rheumatology: How I treat Varun DhirMBBS, MD, DMProfessor, Internal Medicine (Rheumatology Division), PGIMER, Chandigarh Targets of hypertension and choice of antihypertensives. Despite a lowering of blood pressure cut-off for treatment to 130/80...
